<qa>  How many CHC patients will be enrolled in the IFN-alpha treatment?This is a 26 week study examining the ability of paroxetine Paxil to prevent the development of depression and neurotoxicity in patients receiving either 3 million units of subcutaneous IFNinterferon-alpha-2b 3 timesweek plus ribavirin, 1000-1200 mgd or PEG polyethylene glycol interferon-alpha-2b 1.5 microgramskg one time a week and ribavirin 800 to 1,400 mg a day for chronic hepatitis C CHC. The IFN plasma half life t12 of 24 to 34 hours of PEG, a CHC treatment recently approved by the FDA, is significantly prolonged allowing for once a week dosing. Studies indicate that the side effect profile of the two forms of IFN-alpha treatment are very similar. CHC patients will be screened for study eligibility, and a total of 100 CHC patients between the ages of 18 and 65 years old will be enrolled across three sites 30 at Emory site and a combination of 30 from the University of Pennsylvania, Rush-Presbyterian-Saint Lukes Medical Center in Chicago and Montefiore Medical Center in New York. Two weeks prior to treatment with subcutaneous IFN-alpha-2b, patients who meet inclusion and exclusion criteria will be stratified on the basis of a history of major depression and then randomly assigned to paroxetine or placebo in double blind fashion. 